Guerbet
Research Guerbet (0ELV) on Bullrun: P/E 3.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker0ELV
- ExchangeLSE
- CountryFrance
- CurrencyEUR
- P/E3.1
- Financial periodFY2025
- RevenueEUR 786.44M
- Revenue growth-6.5%
- Net income-EUR 112.65M
- Free cash flowEUR 51.23M
Valuation Snapshot
P/E is 3.1.
Peer valuation comparison
Latest P/E is 3.05x versus a France median of 15.25x (80.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 786.44M | -EUR 112.65M | EUR 51.23M | n/a | -8.91 | EUR 115.52M | n/a | EUR 266.99M |
| FY2024 | EUR 841.09M | EUR 13.47M | EUR 49.18M | n/a | 1.07 | EUR 50.24M | n/a | EUR 394.24M |
| FY2023 | EUR 785.69M | EUR 22.17M | -EUR 14.12M | n/a | 1.75 | EUR 51.28M | n/a | EUR 378.27M |
| FY2022 | EUR 753.28M | -EUR 41.12M | -EUR 13.39M | n/a | -3.25 | EUR 41.68M | n/a | EUR 379.57M |
| FY2021 | EUR 732.07M | EUR 32.64M | EUR 78.47M | n/a | 2.58 | EUR 115.73M | n/a | EUR 405.09M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-26 | n/a | 3.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Guerbet
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.
Related stock research
Other related stocks
Frequently asked questions
What is Guerbet's P/E ratio?
Guerbet's price-to-earnings (P/E) ratio is 3.1.
What does Guerbet do?
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.